AI designs peptides for ‘undruggable’ diseases
A new AI-powered approach is tackling the challenge of 'undruggable' diseases by designing peptides that can bind to and destroy previously untreatable proteins.
List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
A new AI-powered approach is tackling the challenge of 'undruggable' diseases by designing peptides that can bind to and destroy previously untreatable proteins.
A new targeted radiotherapy offers hope for patients with rare neuroendocrine tumours, demonstrating a significant improvement in progression-free survival in a key clinical trial.
Rigel Pharmaceuticals has announced the enrolment of the first patient in a Phase I trial evaluating fostamatinib for sickle cell disease.
A new study suggests that targeting serotonin in the gut, rather than the brain, could lead to antidepressants with fewer side effects.
UVA researchers found that continuous glucose monitor data can predict nerve, eye, and kidney damage in type 1 diabetes.
Grifols has received a $21 million grant from The Michael J. Fox Foundation to fund a pioneering study aimed at identifying early biomarkers for Parkinson's disease (PD).
Researchers at the University of Virginia School of Medicine have developed computer models to create more targeted antibiotics. This approach aims to fight antibiotic resistance by focusing on specific bacteria in different parts of the body, reducing the reliance on broad-spectrum antibiotics.
Bio-Rad has launched Nuvia wPrime 2A Media, a scalable resin designed for biomolecule purification in research and biotherapeutic applications.
Macrocycles outperform traditional therapeutics on several fronts, yet they account for just four percent of FDA-approved drugs. Colleagues Ann E Cleves and Ajay N Jain from Optibrium Ltd explain why we can expect to see this number increase in the coming years.
LB Pharmaceuticals announced positive Phase II results for LB-102, showing significant symptom improvement in schizophrenia with a favourable safety profile.
In part two of the step-by-step scientific workflow for drug discovery series, Dr Raminderpal Singh and Nina Truter describe the functions of the workflow previously outlined and include key considerations.
Learn how Kindeva and Emervax are advancing vaccine delivery with painless, needle-free technology designed to improve accessibility and uptake worldwide.
A Virginia Tech student is investigating new treatments for lupus, an autoimmune disease that affects millions worldwide.
9 January 2025 | By Eurofins DiscoverX
Gain valuable insights into the latest advancements in obesity drug discovery and enhance your research capabilities.
Find out how Confo Therapeutics is overcoming challenges in GPCR drug development to create next-gen therapies for metabolic diseases.